Targeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro

INDUSTRY SYMPOSIUM

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro

From Our Annual Summit

ILCS Sessions

ILCS 2025

Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

Targeting EGFR and ALK in NSCLC

} 26 min

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

} 25 min

Rare But Actionable: How To Target for RET, METex14 and NTRK

} 20 min

Current Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

} 25 min

A. Dingemans

Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin

Dec 18 2025

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard

Jul 10 2025

O. GautschiJ. NaidooN. Girard

Targeted Therapies in NSCLC

} 1h 30 min

The Reading Room

Articles & Research

Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles

KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials

V. Noronha

Oct 02 2026

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

Oct 01 2026

B. RicciutiJ. RemonD. Planchard

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

Sep 25 2026

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw

Sep 23 2026

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

D. Planchard

Sep 16 2026

SCLCTargeted Therapies

Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan

Sep 15 2026

Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead

ARROS-1: first-line zidesamtinib responds in over 90% of ROS1-positive NSCLC

Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

PAPILLON final OS: 34.3 vs 27.9 months, HR 0.87 not significant after 76% crossover

REZILIENT 3: zipalertinib plus chemotherapy adds six months of first-line PFS

Sep 04 2026

An EGFR-SHC1 fusion resists EGFR inhibitors through its non-kinase partner

Aug 31 2026

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

H. Horinouchi

Aug 27 2026

Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

J. RemonR. Ferrara

Industry Sponsored

Featured Sessions

Jul 20 2026

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro

INDUSTRY SYMPOSIUM

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro

From Our Annual Summit

ILCS Sessions

ILCS 2025

Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

Targeting EGFR and ALK in NSCLC

} 26 min

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

} 25 min

Rare But Actionable: How To Target for RET, METex14 and NTRK

} 20 min

Current Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

} 25 min

A. Dingemans

Expert Insights

Webinars

Dec 18 2025

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

Jul 10 2025

O. GautschiJ. NaidooN. Girard

Targeted Therapies in NSCLC

} 1h 30 min

The Reading Room

Articles & Research

Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles

KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials

V. Noronha

Oct 02 2026

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

Oct 01 2026

B. RicciutiJ. RemonD. Planchard

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

Sep 25 2026

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw

Sep 23 2026

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Sep 18 2026

INDUSTRY NEWS

Sevabertinib approved in the US for untreated HER2-mutant NSCLC

Sep 17 2026

Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA

Sep 17 2026

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

D. Planchard

Sep 16 2026

SCLCTargeted Therapies

Tam-Peli extended median OS to 13.3 months in relapsed SCLC, against 9.4 months with topotecan

Sep 15 2026

Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead

ARROS-1: first-line zidesamtinib responds in over 90% of ROS1-positive NSCLC

Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

PAPILLON final OS: 34.3 vs 27.9 months, HR 0.87 not significant after 76% crossover

REZILIENT 3: zipalertinib plus chemotherapy adds six months of first-line PFS

Sep 04 2026

An EGFR-SHC1 fusion resists EGFR inhibitors through its non-kinase partner

Aug 31 2026

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

H. Horinouchi

Aug 27 2026

Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

J. RemonR. Ferrara

Aug 25 2026

M. HochmairH. HorinouchiD. Planchard

ALINA: fewer patients stopped adjuvant alectinib than chemotherapy; quality-of-life gains held to two years

Aug 08 2026

Advanced NSCLCBiomarkersTargeted Therapies

EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R

B. Ricciuti

Aug 06 2026

ORCHARD final data: modest benefit for osimertinib plus gefitinib in EGFR C797X, and no further study advised

X. LeZ. Piotrowska

Aug 06 2026

Adjuvant crizotinib did not prolong DFS in resected ALK-positive NSCLC

J. Sands

Aug 04 2026

L858R with a TP53 co-mutation halved real-world PFS on front-line osimertinib

H. Borghaei

Jul 23 2026

INDUSTRY NEWS

Zidesamtinib approved in the US for previously treated ROS1-positive NSCLC

Jul 13 2026

INDUSTRY NEWS